KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Equity Average (2021 - 2025)

Historic Equity Average for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to $983.0 million.

  • Recursion Pharmaceuticals' Equity Average rose 7728.4% to $983.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $983.0 million, marking a year-over-year increase of 7728.4%. This contributed to the annual value of $749.1 million for FY2024, which is 5783.31% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Equity Average stood at $983.0 million, which was up 7728.4% from $926.5 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Equity Average peaked at $984.4 million during Q1 2025, and registered a low of -$219.7 million during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $465.6 million (2022), whereas its average is $525.0 million.
  • The largest annual percentage gain for Recursion Pharmaceuticals' Equity Average in the last 5 years was 33593.37% (2022), contrasted with its biggest fall of 3351.19% (2022).
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Equity Average stood at $571.0 million in 2021, then decreased by 23.48% to $436.9 million in 2022, then increased by 3.15% to $450.7 million in 2023, then soared by 72.99% to $779.7 million in 2024, then increased by 26.08% to $983.0 million in 2025.
  • Its Equity Average stands at $983.0 million for Q3 2025, versus $926.5 million for Q2 2025 and $984.4 million for Q1 2025.